NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, detailing continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo (DRC). The company has already obtained regulatory approval for the trial in the DRC, marking a significant step in the clinical validation of its nanoviricide technology platform.
Beyond MPox, NanoViricides outlined progress in its orphan-first regulatory strategy. Subsequent to the quarter, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for NV-387 as a treatment for measles. The company has also submitted additional applications targeting MPox and smallpox. Orphan drug designation provides incentives such as tax credits for clinical trials and seven-year market exclusivity upon approval, potentially accelerating the development timeline and reducing financial burdens.
NV-387 is a broad-spectrum antiviral drug candidate designed to treat multiple viral diseases, including respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, MPox, smallpox, and measles. The drug is based on NanoViricides' proprietary nanoviricide technology, which uses specially designed nanomaterials to target and neutralize viruses. The company believes NV-387's mechanism of action could overcome resistance issues associated with traditional small-molecule antivirals.
NanoViricides is also advancing other drug candidates, including NV-CoV-2 (API NV-387) for COVID-19 and NV-CoV-2-R, which encapsulates the approved drug remdesivir within its polymeric micelles. The company highlights that remdesivir's existing FDA approval could facilitate a more straightforward regulatory path for NV-CoV-2-R, assuming comparable safety profiles.
Investors can access the full press release and additional updates via the company's newsroom at https://ibn.fm/NNVC. The company cautions that drug development is inherently lengthy and capital-intensive, with no guarantee of eventual clinical or commercial success. However, the recent regulatory milestones for NV-387 represent tangible progress toward addressing significant unmet medical needs in viral diseases.
